Trial site
SSM Health Saint Louis University Hospital
St Louis, Missouri 63104, United StatesNot linked to an institution yet
- 17running trials
- 8closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 26 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting15 trials
- Completed6 trials
- Recruiting2 trials
- Terminated2 trials
- Lead sponsor
- National Cancer Institute (NCI)10 trials
- NRG Oncology3 trials
- Curium US LLC2 trials
- Gilead Sciences2 trials
- American Heart Association1 trial
- and 7 more
Running trials
Active, not recruiting
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151· Phase 3· Curium US LLC· Source
Active, not recruiting
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331· Phase 2· Fusion Pharmaceuticals Inc.· Source
Active, not recruiting
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755· Medtronic Cardiovascular· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374· Phase 3· GT Medical Technologies, Inc.· Source
Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537· Phase 2/3· NRG Oncology· Source
Contact: Sean Massa (principal investigator)
Recruiting
APOL1 Genetic Testing in African Americans
NCT05656261· St. Louis University· Source
Contact: Krista Lentine, PhD, MD
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Active, not recruiting
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02443077· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00977574· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
NCT00792948· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT00569127· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499· Phase 2· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error